Genedrive (GDR) H1 2026 earnings summary

Executive summary

• Expanded commercial operations in the UK and internationally, focusing on rapid pharmacogenetic testing solutions.

• Achieved NHS implementation guidance and procurement system acceptance for key products.

• Secured significant post-period funding to support commercialisation and product development.

Financial highlights

• Revenue and other income for H1 2025/26 was £0.57m, up from £0.35m year-over-year.

• Diagnostics costs increased to £2.3m (H1 2024/25: £2.1m); administration costs remained stable at £856k.

• Operating loss was £2.6m, unchanged from the prior year period.

• Loss after taxation was £2.4m (H1 2024/25: £2.3m); basic loss per share improved to 0.3p from 0.4p.

• Cash at 31 December 2025 was £0.4m, increasing to £3.65m by 27 March 2026 after fundraising.

Outlook and guidance

• Well-funded to support operational expansion, product development, and market access initiatives.

• FY26 visible revenue of £0.8m expected to increase, supported by UK and international sales traction.

• Anticipates improvement in NHS funding and market conditions in the new financial year, with phased recovery over 12 months.

• Focused on advancing regulatory milestones, including FDA submissions, and generating real-world evidence.